Patients who say their eyes feel dry, gritty, or burning are among the most common in ophthalmology, and treating them well ...
LUCIA, the second of 2 pivotal phase 3 trials in neovascular (wet) age-related macular degeneration (AMD), missed its primary ...
The 2 complement inhibitors approved by the US Food and Drug Administration (FDA) for geographic atrophy (GA) secondary to ...
The FDA has approved Alcon’s apraclonidine ophthalmic solution 0.125% (Brytly), an over-the-counter eye drop for redness ...
SpyGlass Pharma has reported 4-year interim results from the first-in-human (FIH) trial of its Bimatoprost Drug Pad-IOL System (BIM-IOL System), extending what the company describes as the “longest ...
At AAO 2026, Anjum F. Koreishi, MD, shared how to prevent complications after cataract surgery in patients with uveitis.
David F. Chang, MD, shares how to set realistic refractive IOL expectations and streamline patient counseling.
Timothy Janetos, MD, explained when to refer uveitis to a specialist and why access to uveitis care remains limited.
Taken together, these three responses point to gaps beyond the next therapy: in how academic medicine is valued, in what ...
A higher risk of central serous chorioretinopathy and serous pigment epithelial detachment are associated with varicose veins.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results